Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Itziar Irurzun‐Arana"'
Autor:
Nicolás Marco‐Ariño, Sergio Vide, Mercè Agustí, Andrew Chen, Sebastián Jaramillo, Itziar Irurzun‐Arana, Adrià Pacheco, Carmen Gonzalez, Erik W. Jensen, Patricia Capsi‐Morales, José F. Valencia, Iñaki F. Troconiz, Pedro L. Gambus, Merlin D. Larson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 5, Pp 581-593 (2022)
Abstract Intraoperative targeting of the analgesic effect still lacks an optimal solution. Opioids are currently the main drug used to achieve antinociception, and although underdosing can lead to an increased stress response, overdose can also lead
Externí odkaz:
https://doaj.org/article/9f611121b92c4e7dbb2b721331878380
Autor:
Simon Smith, Woong-Yang Park, Kyoung-Mee Kim, Jeeyun Lee, Jung Yong Hong, Seung Tae Kim, Won Ki Kang, Emma Dean, Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Peter G S Mortimer, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator o
Externí odkaz:
https://doaj.org/article/0fb079375db848879a747baa38eb0c19
Autor:
Meera Varshneya, Itziar Irurzun-Arana, Chiara Campana, Rafael Dariolli, Amy Gutierrez, Taylor K. Pullinger, Eric A. Sobie
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 2, Pp 100-107 (2021)
Many drugs that have been proposed for treatment of coronavirus disease 2019 (COVID‐19) are reported to cause cardiac adverse events, including ventricular arrhythmias. In order to properly weigh risks against potential benefits, particularly when
Externí odkaz:
https://doaj.org/article/7e128337b2e345fdb76274f4167301cb
Publikováno v:
PLoS Computational Biology, Vol 14, Iss 4, p e1006087 (2018)
Numerous problems encountered in computational biology can be formulated as optimization problems. In this context, optimization of drug release characteristics or dosing schedules for anticancer agents has become a prominent area not only for the de
Externí odkaz:
https://doaj.org/article/0bcdb17acf53406883c086be3a8bc394
Autor:
Violeta Balbas-Martinez, Leire Ruiz-Cerdá, Itziar Irurzun-Arana, Ignacio González-García, An Vermeulen, José David Gómez-Mantilla, Iñaki F Trocóniz
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0192949 (2018)
The literature on complex diseases is abundant but not always quantitative. This is particularly so for Inflammatory Bowel Disease (IBD), where many molecular pathways are qualitatively well described but this information cannot be used in traditiona
Externí odkaz:
https://doaj.org/article/3b6ec81c41dd47a1a58e893e2d6640ab
Supplemental data for the main manuscript. Contains equation description of the main features of the framework, description of the pharmacokinetic models and parameter estimates used for the simulations of the treatment effects, additional model fitt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bff38366826696fdd68980f0cb5715a5
https://doi.org/10.1158/0008-5472.22426344.v1
https://doi.org/10.1158/0008-5472.22426344.v1
Identification of optimal schedules for combination drug administration relies on accurately estimating the correct pharmacokinetics, pharmacodynamics, and drug interaction effects. Misspecification of pharmacokinetics can lead to wrongly predicted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::313c92ef4e40b67ca550e5502e5bc06d
https://doi.org/10.1158/0008-5472.c.6512310.v1
https://doi.org/10.1158/0008-5472.c.6512310.v1
Quick guide to model assumptions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35cd4a7b78e552e89dc88cc530d6d399
https://doi.org/10.1158/0008-5472.22426347
https://doi.org/10.1158/0008-5472.22426347
Autor:
Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, Seung Tae Kim
Purpose:Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.Patients and Methods:Eligible patients with solid tumors, enriched for melanoma, received cerala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc7339c2ee702e3eb8aed960329ad70
https://doi.org/10.1158/1078-0432.c.6530478
https://doi.org/10.1158/1078-0432.c.6530478
Autor:
Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, Seung Tae Kim
Supplementary Table 1. Treatment Outcomes for individual trial participants and dose cohort (N=57)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b409678377e7ddd68c3f898aa966dc
https://doi.org/10.1158/1078-0432.22480593
https://doi.org/10.1158/1078-0432.22480593